nsclc – Scalper1

Lilly Drug Ramucirumab Boosts Lung Cancer Survival

Big pharma Eli Lilly (LLY) said Wednesday that its drug candidate ramucirumab improved the survival of lung-cancer patients in a late-stage study. Lilly stock gapped up 3% in early trading on the stock market today. The study looked at patients with metastatics non-small-cell lung cancer (NSCLC) who had failed a previous round of platinum-based chemotherapy. One group of patients took standard cancer drug docetaxel (best known as Sanofi’s (SNY)

Bristol-Myers’ New Nivolumab Trial Sparks Worries

Big pharma Bristol-Myers Squibb’s (BMY) stock was selling off nearly 3% in heavy morning trading in the stock market today. There was no news from the company, but one possible reason was that it posted a new clinical trial of nivolumab in non-small-cell lung cancer (NSCLC). The new trial studies only patients with the PD-L1 biomarker, and does not combine nivolumab with any other agents. The company is already conducting another study of the